RARE Quote, Financials, Valuation and Earnings

Geron Corp. has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of -39.02%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat Geron Corp.'s return on equity of -29.65%.

Ultragenyx Pharmaceutical, Inc. has a consensus price target of $81.85, signalling upside risk potential of 124%. On the other hand Geron Corp. has an analysts' consensus of $3.50 which suggests that it could grow by 162.47%. Given that Geron Corp. has higher upside potential than Ultragenyx Pharmaceutical, Inc., analysts believe Geron Corp. is more attractive than Ultragenyx Pharmaceutical, Inc..

Ultragenyx Pharmaceutical, Inc. has a beta of 0.162, which suggesting that the stock is 83.763% less volatile than S&P 500. In comparison Geron Corp. has a beta of 0.567, suggesting its less volatile than the S&P 500 by 43.26%.

Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are larger than Geron Corp. quarterly revenues of $47.2M. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than Geron Corp.'s net income of -$18.4M. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 5.65x versus 4.61x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of -82.06%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Ultragenyx Pharmaceutical, Inc. has a consensus price target of $81.85, signalling upside risk potential of 124%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $85.47 which suggests that it could grow by 4.47%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Ultragenyx Pharmaceutical, Inc. has a beta of 0.162, which suggesting that the stock is 83.763% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.

Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are larger than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 5.65x versus 13.93x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of 38.89%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Ultragenyx Pharmaceutical, Inc. has a consensus price target of $81.85, signalling upside risk potential of 124%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $781.13 which suggests that it could grow by 8.07%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Ultragenyx Pharmaceutical, Inc. has a beta of 0.162, which suggesting that the stock is 83.763% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 5.65x versus 5.59x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of 34.76%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Ultragenyx Pharmaceutical, Inc. has a consensus price target of $81.85, signalling upside risk potential of 124%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $485.36 which suggests that it could grow by 6.12%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Ultragenyx Pharmaceutical, Inc. has a beta of 0.162, which suggesting that the stock is 83.763% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.

Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 5.65x versus 10.10x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.